The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zalyalova Z.A.

Kazan State Medical University;
Republican Consultative and Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy

Katunina E.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical Biological Agency

Pokhabov D.V.

Center for Innovative Neurology, Extrapyramidal Diseases and Botulinum Therapy;
Voino-Yasnevetsky Krasnoyarsk State Medical University

Munasipova S.E.

Kazan State Medical University;
Republican Consultative and Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy

Ermakova M.M.

Kazan State Medical University

Tremor-dominant form of Parkinson’s disease

Authors:

Zalyalova Z.A., Katunina E.A., Pokhabov D.V., Munasipova S.E., Ermakova M.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4): 28‑35

DOI: 10.17116/jnevro202412404128

Views: 1066

Downloaded: 2

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Zalyalova ZA, Katunina EA, Pokhabov DV, Munasipova SE, Ermakova MM. Tremor-dominant form of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):28‑35. (In Russ.)
https://doi.org/10.17116/jnevro202412404128

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

The article is of a review nature and is devoted to tremor, one of the maladaptive and difficult-to-treat symptoms of Parkinson’s disease (PD). Along with the classic rest tremor, patients with PD may experience tremor of other modalities: postural tremor, kinetic tremor, which reflects a multimodal mechanism of tremor formation involving multiple neurotransmitter systems. The unpredictable response to therapeutic options, the ambiguous response to levodopa, also reflects the role of multiple underlying pathophysiological processes. Among the drug methods of tremor correction, preference is given to dopamine receptor agonists — due to the spectrum of their pharmaceutical action, high efficiency in relation to all leading motor and a number of non-motor manifestations. The evidence for advanced neurosurgical, non-invasive modalities is mixed, and there are insufficient comparative studies to assess their efficacy in patients with tremor-dominant forms of PD.

Keywords:

Parkinson’s disease
tremor
resting tremor
postural tremor
kinetic tremor
pathophysiology of tremor
dopamine receptor agonists
piribedil

Authors:

Zalyalova Z.A.

Kazan State Medical University;
Republican Consultative and Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy

Katunina E.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical Biological Agency

Pokhabov D.V.

Center for Innovative Neurology, Extrapyramidal Diseases and Botulinum Therapy;
Voino-Yasnevetsky Krasnoyarsk State Medical University

Munasipova S.E.

Kazan State Medical University;
Republican Consultative and Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy

Ermakova M.M.

Kazan State Medical University

Received:

14.09.2023

Accepted:

23.11.2023

List of references:

  1. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548-560.  https://doi.org/10.1001/jama.2019.22360
  2. Bolezn Parkinsona, vtorichnyi parkinsonizm i drugie zabolevaniya, proyavlyayushchiesya sindromom parkinsonizma. Clinical Recommendations, 2021. (In Russ.).
  3. Zach H, Dirkx M, Bloem BR, et al. The clinical evaluation of Parkinson’s tremor. J Park Dis. 2015;5:471-474.  https://doi.org/10.3233/JPD-150650
  4. Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson’s disease: A clinical and neuroimaging study. Brain. 2018;141:811-821.  https://doi.org/10.1093/brain/awx376
  5. Kipfer S. Resting Tremor in Parkinson Disease. Arc Neurol. 2011;68:1037-1041. https://doi.org/10.1001/archneurol.2011.147
  6. Zalyalova ZA. Drozhatel’nyye fenotipy bolezni Parkinsona. V kn.: Bolezn’ Parkinsona i rasstroystva dvizheniy. Ruk-vo dlya vrachey po materialam II Natsional’nogo kongressa (pod red. Illarioshkina S.N., Levina O.S.). M. 2011;5-59. (In Russ.).
  7. Gironell A, Pascual-Sedano B, Aracil I, et al. Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Park Dis. 2018;56(7):45-50.  https://doi.org/10.1155/2018/4327597
  8. Aleksovski D, Miljkovic D, Bravi D, et al. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci. 2018;39(7):1971-1976. https://doi.org/10.1007/s10072-018-3522-z
  9. Levin OS, Datiyeva VK. Tremor pri bolezni Parkinsona: osobennosti fenomenologii i lecheniya. Sovremennaya Terapiya v Psikhiatrii I Nevrologii. 2014;3(6):14-19. (In Russ.).
  10. Drozhatel’nyye giperkinezy: Rukovodstvo dlya vrachey (Seriya rukovodstv «Dvigatel’nyye rasstroystva») Illarioshkin S.N., Ivanova-Smolenskaya I.A. M.: Izdatel’skiy kholding «Atmosfera»; 2011. (In Russ.).
  11. Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. Curr Opin Neurol. 2020;33(4):474-481.  https://doi.org/10.1097/WCO.0000000000000829
  12. Hallett M. Tremor: pathophysiology. Park Relat Disord. 2014;20(suppl 1):S118-S122. https://doi.org/10.1016/S1353-8020(13)70029-4
  13. Helmich RC, Dirkx MF. Pathophysiology and Management of Parkinsonian Tremor. Semin Neurol. 2017;37:127-134.  https://doi.org/10.1055/s-0037-1601558
  14. Helmich RC. The cerebral basis of Parkinsonian tremor: A network perspective. Mov Dis. 2018;33(7):219-231.  https://doi.org/10.1002/mds.27224
  15. Dirkx MF, Bologna M. The pathophysiology of Parkinson’s disease tremor. J Neurol Sci. 2022;435:120196. https://doi.org/10.1016/j.jns.2022.120196
  16. Timmermann L, Gross J, Dirks M, et al. The cerebral oscillatory network of parkinsonian resting tremor. Brain. 2003;126:199-212.  https://doi.org/10.1093/brain/awg022
  17. Dirkx MF, den Ouden H, Aarts E, et al. The cerebral network of parkinson’s tremor: An effective connectivity fMRI study. J Neurosc. 2016;36:5362-5372. https://doi.org/10.1523/JNEUROSCI.3634-15.2016
  18. Dirkx MF, den Ouden HEM, Aarts E, et al. Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus. Brain. 2017;140:721-734.  https://doi.org/10.1093/brain/aww331
  19. Kremer NI, Pauwels RWJ, Pozzi NG, et al. Deep brain stimulation for tremor: Update on long-term outcomes, target considerations and future directions. J Clin Med. 2021;10(5):23-29.  https://doi.org/10.3390/jcm10163468
  20. Helmich RC, Hallett M, Deuschl G, et al. Cerebral causes and consequences of parkinsonian resting tremor: A tale of two circuits? Brain. 2012;135(8):3206-3226. https://doi.org/10.1093/brain/aws023
  21. Duval C, Daneault JF, Hutchison WD, et al. A brain network model explaining tremor in Parkinson’s disease. Neurobiol Dis. 2016;85:49-59.  https://doi.org/10.1016/j.nbd.2015.10.009
  22. Helmich RC, Janssen MJR, Oyen WJG, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol. 2011;69:269-281.  https://doi.org/10.1002/ana.22361
  23. Underwood CF, Parr-Brownlie LC. Primary motor cortex in Parkinson’s disease: Functional changes and opportunities for neurostimulation. Neurobiol Dis. 2021;147(53):45-49.  https://doi.org/10.1016/j.nbd.2020.105159
  24. Burciu RG, Vaillancourt DE. Imaging of Motor Cortex Physiology in Parkinson’s Disease. Mov Dis. 2018;33:1688-1699. https://doi.org/10.1002/mds.102
  25. Ni Z, Pinto AD, Lang AE, et al. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol. 2010;68:816-824.  https://doi.org/10.1002/ana.22221
  26. Lu MK, Chiou SM, Ziemann U, et al. Resetting tremor by single and paired transcranial magnetic stimulation in Parkinson’s disease and essential tremor. Clin Neurophysiol. 2015;126:2330-2336. https://doi.org/10.1016/j.clinph.2015.02.010
  27. Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Mov Dis. 2012;27:8-30.  https://doi.org/10.1002/mds.23795
  28. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol. 1991;50(6):743-755.  https://doi.org/10.1097/00005072-199111000-00006
  29. Isaias IU, Marotta G, Pezzoli G, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology. 2011;11(6):12-19.  https://doi.org/10.1186/1471-2377-11-88
  30. Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138:2964-2973. https://doi.org/10.1093/brain/awv215
  31. Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: An [123I] β-CIT SPECT study. J Neural Trans. 2008;115:721-729.  https://doi.org/10.1007/s00702-007-0015-2
  32. Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. Park Dis. 2016;34(2):34-39.  https://doi.org/10.1038/npjparkd.2016.1
  33. Lenka A, Jankovic J. Tremor Syndromes: An Updated Review. Front Neurol. 2021;12(7):1-17.  https://doi.org/10.3389/fneur.2021.684835
  34. Hess CW, Pullman SL. Tremor: Clinical phenomenology and assessment techniques. Tremor Other Hyperkin Mov. 2012;2:1-15.  https://doi.org/10.5334/tohm.115
  35. Dirkx MF, Zach H, Bloem BR, et al. The nature of postural tremor in Parkinson disease. Neurology. 2018;90:e1095-102.  https://doi.org/10.1212/WNL.0000000000005215
  36. Gupta DK, et al. Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson’s Disease. Tremor Other Hyperkin Mov. 2020;10(1):1-7.  https://doi.org/10.5334/tohm.552
  37. Golubev VL. Algoritm lecheniya rannikh stadiy bolezni Parkinsona. Atmosfera. Nervnyye Bolezni. 2006;12(4):9-12. (In Russ.).
  38. Tedeschi G. Tremor in Parkinson disease: acute response to oral levodopa. Ital J Neurol Sci. 1990;11(3):259-263.  https://doi.org/10.1007/BF02333855
  39. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. https://doi.org/10.1001/jama.2014
  40. Gigante A. Action tremor in Parkinson’s disease: frequency and relationship to motor and non-motor signs. Eur J Neurol. 2015;22(2):223-228.  https://doi.org/10.1111/ene.12583
  41. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol. 2006;63(3):354-357.  https://doi.org/10.1001/archneur.63.3.354
  42. Govorova TG, Popova TE, Tappakhov AA. Elektrofiziologicheskiye osobennosti tremora pri essentsial’nom tremore i bolezni Parkinsona. V kn.: Botkinskiye chteniya. Vserossiyskiy terapevticheskiy kongress s mezhdunarodnym uchastiyem. 2019;56-57. (In Russ.).
  43. Stebbins GT. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Dis. 2013;28(5):668-670.  https://doi.org/10.1002/mds.25383
  44. De Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. The Lancet Neurol. 2020;19:452-461.  https://doi.org/10.1016/S1474-4422(20)30036-3
  45. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(8):27-42.  https://doi.org/10.1111/ene.14108
  46. Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice Guideline summary. Neurology. 2021;97:942-957.  https://doi.org/10.1212/WNL.0000000000012868
  47. Nonnekes J, Timmer MHM, de Vries NM, et al. Unmasking levodopa resistance in Parkinson’s disease. Mov Dis. 2016;31:1602-1609. https://doi.org/10.1002/mds.26712
  48. Heusinkveld LE, Hacker ML, Turchan M, et al. Impact of tremor on patients with early stage parkinson’s disease. Front Neurol. 2018;9:34-39.  https://doi.org/10.3389/fneur.2018.00628
  49. Zach H, Dirkx M, Pasman JW, et al. The patient’s perspective: The effect of levodopa on Parkinson symptoms. Parkins Rel Dis. 2017;35:48-54.  https://doi.org/10.1016/j.parkreldis.2016.11.015
  50. Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020;95(11):e1461-e1470. https://doi.org/10.1212/WNL.0000000000010316
  51. Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson’s disease. NPJ Parkinsons Dis. 2022;8(1):56-61.  https://doi.org/10.1038/s41531-022-00321-y
  52. Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatr. 2020;91:795-808.  https://doi.org/10.1136/jnnp-2019-322338
  53. Maillet A, Thobois S, Fraix V, et al. Neural substrates of levodopa-responsive gait disorders and freezing in advanced Parkinson’s disease: a kinesthetic imagery approach. Hum Brain Mapp. 2015;36(3):959-980.  https://doi.org/10.1002/hbm.22679
  54. Titova NV, Katunina EA, Tairova RT, et al. Farmakorezistentnyy tremor pri bolezni Parkinsona i essentsial’nom tremore. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(10):24-30. (In Russ.). https://doi.org/10.17116/jnevro202212210124
  55. Gupta HV, Lyons KE, Wachter N, et al. Long Term Response to Levodopa in Parkinson’s Disease. J Parkinsons Dis. 2019;9(3):525-529.  https://doi.org/10.3233/JPD-191633
  56. Caligiuri MP, Lohr JB. Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis. Clin Neuropharmacol. 1993;16(3):244-250.  https://doi.org/10.1097/00002826-199306000-00008
  57. Bogdanov RR. Osobennosti lekarstvennoy terapii nachal’nykh proyavleniy bolezni Parkinsona. Nervnyye Bolezni. 2013;1:2-5. (In Russ.).
  58. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72(6):713-720.  https://doi.org/10.1136/jnnp.72.6.713
  59. Elble RJ. Tremor and dopamine agonists. Neurology. 2002;58(4Suppl1):S57-S62.  https://doi.org/10.1212/WNL.58.suppl_1.S57
  60. Navan P, Findley LJ, Jeffs JA, et al. Double-blind, single- dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s disease. Mov Disord. 2003;18(2):176-180.  https://doi.org/10.1002/mds.10320
  61. Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019;33:905-918.  https://doi.org/10.1007/s40263-019-00661-z
  62. Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatr. 1990;53:1004-1007. https://doi.org/10.1136/jnnp.53.11.1004
  63. Millan MJ. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson disease. Pharmacol Therap. 2010;128(2):229-273.  https://doi.org/10.1016/j.pharmthera.2010.06.002
  64. Gobert A, Di Cara B, Cistarelli L, et al. Piribedil enhances frontocortical andhippocampal release of acetylcholine in freely moving rats by blockade of α2a-adrenoceptors: A dialysis comparison to Talipexole and Quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther. 2003;305(1):338-346.  https://doi.org/10.1124/jpet.102.046383
  65. Evidente VG, Esteban RP, Domingo FM, et al. Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: the Asian experience. Park Rel Disord. 2003;10(2):117-121.  https://doi.org/10.1016/s1353-8020(03)00096-8
  66. Pilipovich AA, Golubev VL. Vozmozhnosti primeneniya piribedila s tochki zreniya dokazatel’noy meditsiny. RMZH. 2018;26(12-1):39-43. (In Russ.).
  67. Fedorova NV, Artemieva EG, Chigir IP, et al. Use of Pronoran (Piribedil) in Parkinsons disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2003;103(9):71-72. (In Russ.).
  68. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicenter study. J Neurol. 1992;239(suppl 1):S28-S34. 
  69. Mentenopolous G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease. Clin Neuropharm. 1989;12:23-28. 
  70. Evrard Y. Piribedil, a dopaminergic agonist. JAMA. 1991;34(8):16-20. 
  71. Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91:e189-201.  https://doi.org/10.1212/WNL.0000000000005816
  72. Djaldetti R, Mosberg-Galili R, Sroka H, et al. Camptocormia (BentSpine) in patients with Parkinson’s disease characterization and possible pathogenesis of an unusual phenomenon. Mov Dis. 1999;14(3):443-447.  https://doi.org/10.1002/1531-8257(199905)14:3<443::aid-mds1009>3.0.co;2-g
  73. Suzuki M, Hirai T, Ito Y, et al. Pramipexole-induced antecollis in Parkinson’s disease. J Neurol Sci. 2008;264(1-2):195-197.  https://doi.org/10.1016/j.jns.2007.08.008
  74. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-1053. https://doi.org/10.1001/archneur.61.7.1044
  75. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484-1491. https://doi.org/10.1056/NEJM200005183422004
  76. Marras C, Chaudhuri KR, Titova N, et al. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics. 2020;17:1366-1377. https://doi.org/10.1007/s13311-020-00894-7
  77. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database of Systematic Reviews. 2002;3:CD003735. https://doi.org/10.1002/14651858.CD003735
  78. Saeedi Y, Ghadimi M, Rohani M, et al. Impact of anticholinergic drugs withdrawal on motor functionvin patients with Parkinson’s disease. Clin Neurol Neurosurg. 2021;202(3):106480. https://doi.org/10.1016/j.clineuro.2021.106480
  79. Van Hilten JJ, Ramaker CC, Stowe R, et al. Bromocriptine versus levodopa in early Parkinson’s disease. Cochrane Database Syst Rev. 2007;2007(4):CD002258. https://doi.org/10.1002/14651858.CD002258.pub2
  80. Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson’s disease. Front Aging Neurosci. 2014;6:1-9.  https://doi.org/10.3389/fnagi.2014.00180
  81. Lew MF. Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci. 2013;123:859-865.  https://doi.org/10.3109/00207454.2013.812085
  82. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol. 2011;18(12):1373-1378. https://doi.org/10.1111/j.1468-1331.2011.03512.x
  83. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757-763.  https://doi.org/10.1056/NEJM199903113401003
  84. Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Mov Dis Clin Prac. 2016;3(6):116-124.  https://doi.org/10.1002/mdc3.12266
  85. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: A retrospective analysis of a large multicentered clinical experience. Mov Dis. 1998;13:377-382.  https://doi.org/10.1002/mds.870130302
  86. Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010;33(1):14-16.  https://doi.org/10.1097/WNF.0b013e3181c47168
  87. Crosby NJ, Deane K, Clarke CE. Beta-blocker therapy for tremor in Parkinson’s disease. Cochrane Database of Systematic Reviews. 2003;CD003361. https://doi.org/10.1002/14651858.CD003361
  88. Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013;73:1405-1415. https://doi.org/10.1007/s40265-013-0105-4
  89. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging. 2000;16(4):273-278.  https://doi.org/10.2165/00002512-200016040-00003
  90. Abusrair AH, Elsekaily W, Bohlega S.Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies. Tremor Other Hyperkinet Mov. 2022;12:29.  https://doi.org/10.5334/tohm.712
  91. Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Dis. 1994;9(6):601-609.  https://doi.org/10.1002/mds.870090604
  92. Mittal SO, Pandey S. Botulinum toxin for the treatment of tremor. J Neurol Sci. 2022;435:120203. https://doi.org/10.1016/j.jns.2022.120203
  93. Mittal SO, Jog M, Lee J, et al. Novel botulinum toxin injection protocols for parkinson tremor and essential tremor — the yale technique and sensor-based kinematics procedure for safe and effective treatment. Tremor Other Hyperkinet Mov. 2020;10:1-8.  https://doi.org/10.5334/tohm.582
  94. Niemann N, Jankovic J. Botulinum toxin for the treatment of hand tremor. Toxins (Basel). 2018;10:1-10.  https://doi.org/10.3390/toxins10070299
  95. Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS ONE. 2017;12:1-19.  https://doi.org/10.1371/journal.pone.0178670
  96. Larson PS. Deep brain stimulation for movement disorders. Neurotherapeutics. 2014;11(3):465-474.  https://doi.org/10.1007/s13311-014-0274-1
  97. Uc EY, Follett KA. Deep brain stimulation in movement disorders. Semin Neurol. 2007;27(2):170-182.  https://doi.org/10.1055/s-2007-971175
  98. Herrington TM, Cheng JJ, Eskandar EN. Mechanisms of deep brain stimulation. J Neurophysiol. 2016;115(12):19-38.  https://doi.org/10.1152/jn.00281.2015
  99. Chiken S, Nambu A. Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption? Neuroscientist. 2016;22(8):313-322.  https://doi.org/10.1177/1073858415581986
  100. Mao Z, Ling Z, Pan L, et al. Comparison of efficacy of deep brain stimulation of different targets in Parkinson’s disease: A network meta-analysis. Front Aging Neurosci. 2019;10(8):1-8.  https://doi.org/10.3389/fnagi.2019.00023
  101. Honey CR, Hamani C, Kalia SK, et al. Deep Brain Stimulation Target Selection for Parkinson’s Disease. Can J Neurol Sci. 2017;44:3-8.  https://doi.org/10.1017/cjn.2016.22
  102. Wong JK, Viswanathan VT, Nozile-Firth KS, et al. STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson’s Disease. Front Hum Neurosci. 2020;14:578615. https://doi.org/10.3389/fnhum.2020.578615
  103. Lin Z, Zhang X, Wang L, et al. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson’s Disease. Front Hum Neurosci. 2021;15(5):1-10.  https://doi.org/10.3389/fnhum.2021.604433
  104. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson’s Disease: Executive Summary. Neurosurg. 2018;82(6):753-756.  https://doi.org/10.1093/neuros/nyy037
  105. Walters H, Shah BB. Focused Ultrasound and Other Lesioning Therapies in Movement Disorders. Curr Neurol Neurosci Rep. 2019;19:66-71.  https://doi.org/10.1007/s11910-019-0975-2
  106. Ohye C, Higuchi Y, Shibazaki T, et al. Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurg. 2012;70(3):526-536.  https://doi.org/10.1227/NEU.0b013e3182350893
  107. Berg D, Corvol J. European Academy of Neurology/Movement Disorder Society — European Section Guideline on the Treatment of Parkinson’s Disease. Invasive Ther. 2022;37:1360-1374. https://doi.org/10.1002/mds.29066
  108. Lin Z, Zhang C, Li D, et al. Preoperative Levodopa Response and Deep Brain Stimulation Effects on Motor Outcomes in Parkinson’s Disease: A Systematic Review. Mov Disord Clin Pract. 2021;9(2):140-155.  https://doi.org/10.1002/mdc3.13379
  109. Krishna V, Sammartino F, Cosgrove R, et al. Predictors of Outcomes After Focused Ultrasound Thalamotomy. Neurosurg. 2020;87:229-237.  https://doi.org/10.1093/neuros/nyz417
  110. Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017;74(9):1412-1418. https://doi.org/10.1001/jamaneurol.2017.3098
  111. Galimova RM, Krekotin DK, Kachemayeva OV, et al. Terapiya fokusirovannym ul’trazvukom pod kontrolem magnitno-rezonansnoy navigatsii dvigatel’nykh narusheniy pri bolezni Parkinsona i essentsial’nom tremore. V knige: IX Vserossiyskiy s»yezd neyrokhirurgov. Sbornik tezisov. M. 2021;91-92. (In Russ.).
  112. Martinez-Fernandez R, Mahendran S, Pineda-Pardo JA, et al. Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study. J Neurol Neurosurg Psychiatry. 2021;92:927-931.  https://doi.org/10.1136/jnnp-2020-325278
  113. Xu Y, He Q, Wang M, et al. Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson’s disease: a systematic review. Neurosurg Rev. 2021;44:115-127.  https://doi.org/10.1007/s10143-019-01216-y
  114. Chalah MA, Lefaucheur JP, Ayache SS. Non-invasive central and peripheral stimulation: New hope for essential tremor? Front Neurosci. 2015;9:1-11.  https://doi.org/10.3389/fnins.2015.00440
  115. Meng L, Jin M, Zhu X, et al. Peripherical Electrical Stimulation for Parkinsonian Tremor: A Systematic Review. Front Aging Neurosci. 2022;14:1-11.  https://doi.org/10.3389/fnagi.2022.795454

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.